MARKET

CTLT

CTLT

Catalent
NYSE

Real-time Quotes | Nasdaq Last Sale

141.34
+0.32
+0.23%
After Hours: 141.24 -0.1 -0.07% 19:45 09/24 EDT
OPEN
140.48
PREV CLOSE
141.02
HIGH
141.71
LOW
140.18
VOLUME
614.39K
TURNOVER
--
52 WEEK HIGH
142.64
52 WEEK LOW
79.65
MARKET CAP
24.15B
P/E (TTM)
45.46
1D
5D
1M
3M
1Y
5Y
Catalent Prices Upsized Offering of $650 Million Senior Notes
MT Newswires · 1d ago
BRIEF-Catalent Announces Upsizing And Pricing Of Private Offering Of Senior Unsecured Notes Due 2030
reuters.com · 1d ago
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030
Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned...
Business Wire · 1d ago
BRIEF-Catalent Launches Private Offering Of $450 Mln Of Senior Unsecured Notes Due 2030
reuters.com · 2d ago
Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030
Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned...
Business Wire · 2d ago
Catalent Subsidiary to Launch $450 Million Notes Offering
MT Newswires · 2d ago
BRIEF-Catalent Inc Says CEO John Chiminski's 2021 Total Compensation Was $12.6 Million
reuters.com · 09/17 14:08
BRIEF-Catalent Signs Commercial Supply Agreement With Phathom Pharmaceuticals
reuters.com · 09/16 14:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTLT. Analyze the recent business situations of Catalent through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTLT stock price target is 150.92 with a high estimate of 168.00 and a low estimate of 122.00.
EPS
Institutional Holdings
Institutions: 634
Institutional Holdings: 185.73M
% Owned: 108.70%
Shares Outstanding: 170.86M
TypeInstitutionsShares
Increased
200
7.99M
New
63
1.69M
Decreased
170
5.81M
Sold Out
48
1.94M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
John Chiminski
President/Chief Operating Officer
Alessandro Maselli
Chief Financial Officer/Senior Vice President
Thomas Castellano
Corporate Executive
Jonathan Arnold
Corporate Executive
Karen Flynn
Corporate Executive
Aristippos Gennadios
Corporate Executive
Ricci Whitlow
Chief Human Resource Officer/Senior Vice President
Ricardo Pravda
Senior Vice President/Chief Information Officer
Charles Lickfold
Senior Vice President/General Counsel/Secretary
Steven Fasman
Senior Vice President
Michael Grippo
Senior Vice President
Scott Gunther
Senior Vice President
Kay Schmidt
Vice President
Z Mahdavi
Lead Director/Independent Director
Jack Stahl
Independent Director
Madhavan Balachandran
Independent Director
Michael Barber
Independent Director
J. Martin Carroll
Independent Director
Rolf Classon
Independent Director
Rosemary Crane
Independent Director
John Greisch
Independent Director
Christa Kreuzburg
Independent Director
Gregory Lucier
Independent Director
Donald Morel
Independent Director
Peter Zippelius
No Data
About CTLT
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

Webull offers kinds of Catalent Inc stock information, including NYSE:CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.